Moelis & Co
No enriched coverage for $MC in the last 7 days.
No SEC Form 4 filings for $MC in the last 30 days.
See all $MC insider activity →Moelis & Company's average stock price target was reduced from $69.5 to $68.7 by 10 analysts, with a range of $58 to $86. This implies a 22% upside from the Oct. 7 closing price. The consensus rating is 'Buy' among 11 analysts, with 4 Buys, 6 Holds, and 1 Sell. According to FactSet.
Analysts made several rating changes: UBS upgraded Invesco (IVZ) to Buy with a $41 target, Raymond James initiated M&T Bank (MTB) as Outperform with a $250 target, Morgan Stanley upgraded Nexa Resources (NEXA) to Overweight, and others. KeyBanc upgraded Corteva (CTVA) to Overweight with a $17 target, Jefferies upgraded Ambiq Micro (AMBQ) to Buy with a $90 target, and Citi upgraded Flutter to Buy with a $91 target.
UBS upgraded Moelis & Company (MC) to Neutral from Sell, lowering its price target to $59. The bank cited a reset in stock valuation and a challenging M&A backdrop, particularly in sponsor activity. Moelis's Q2 2026 earnings beat expectations, with $0.63 EPS on $409.4M revenue, a 12% year-over-year increase. The company faces challenges related to Saudi Arabia's regional headquarters requirements.
Recent MC coverage spans financial news, earnings and insider activity.
Moelis & Company's average stock price target was reduced from $69.5 to $68.7 by 10 analysts, with a range of $58 to $86. This implies a 22% upside from the Oct. 7 closing price. The consensus rating is 'Buy' among 11 analysts, with 4 Buys, 6 Holds, and 1 Sell. According to FactSet.
Outperform rating may boost the stock.
Neutral rating and lower target suggest limited upside and potential downside pressure.
A modest insider sale by a director may signal limited confidence but the amount is small relative to the company's float.
Modest earnings beat supports incremental upside.
AlphAI scores every news story that mentions MC with an AI model for sentiment and relevance, and aggregates insider trades from Moelis & Co's SEC EDGAR Form 4 filings. Figures refresh continuously.
Moelis & Company's average stock price target was reduced from $69.5 to $68.7 by 10 analysts, with a range of $58 to $86. This implies a 22% upside from the Oct. 7 closing price. The consensus rating is 'Buy' among 11 analysts, with 4 Buys, 6 Holds, and 1 Sell. According to FactSet.
1 min readAnalysts made several rating changes: UBS upgraded Invesco (IVZ) to Buy with a $41 target, Raymond James initiated M&T Bank (MTB) as Outperform with a $250 target, Morgan Stanley upgraded Nexa Resources (NEXA) to Overweight, and others. KeyBanc upgraded Corteva (CTVA) to Overweight with a $17 target, Jefferies upgraded Ambiq Micro (AMBQ) to Buy with a $90 target, and Citi upgraded Flutter to Buy with a $91 target.
2 min readUBS upgraded Moelis & Company (MC) to Neutral from Sell, lowering its price target to $59. The bank cited a reset in stock valuation and a challenging M&A backdrop, particularly in sponsor activity. Moelis's Q2 2026 earnings beat expectations, with $0.63 EPS on $409.4M revenue, a 12% year-over-year increase. The company faces challenges related to Saudi Arabia's regional headquarters requirements.
2 min readShropshire Kenneth sold 1,881 shares of Moelis & Co (MC) at $69.06 ($0.13M total) on 2026-08-27.
1 min readPerella Weinberg (PJT) reported flat revenue of $156.5M, beating EPS estimates, with stock up 7.1%. Houlihan Lokey (HLI) saw revenue drop 15.6% to $511M, missing estimates, with stock down 8%. Goldman Sachs (GS) reported $20.34B revenue, up 39.5%, beating estimates, but stock down 4%. Moelis (MC) reported $409.4M revenue, up 12%, beating estimates, with stock up 2.5%.
2 min readA Q2 recap of 15 investment banking and brokerage stocks says the group’s revenues beat analysts’ consensus by 4.5%, while next-quarter guidance was 1.1% below. Raymond James (RJF) reported $3.93B revenue (+15.6% YoY), beating by 1.4%. Houlihan Lokey (HLI) reported $511M revenue (-15.6%), missing by 16.3%.
7 min readWATANABE OSAMU R. (General Counsel, Secretary) sold 4,850 shares of Moelis & Co (MC) at $69.30 ($0.34M total) on 2026-08-04.
1 min readMoelis & Company (NYSE: MC) reported Q2 CY2026 results. Revenue rose 12% year on year to $409.4 million, exceeding Wall Street estimates by 5.6%, according to the company. Non-GAAP profit was $0.63 per share, 3.2% above analysts’ consensus, also per the company.
2 min readMoelis & Co (MC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Moelis & Company Reports Second Quarter and First Half 2026 Financial Results; Declares Regular Quarterly Dividend of $0.65 Per Share • Record second quarter revenues of $409.4 million, up 12% from the prior year period • Record first half revenues of $729.2 million,
4 min readAfter strong Q2 earnings at major banks driven by higher investment banking and trading revenues, Moelis and Lazard shares rose in the afternoon. The article cites a “booming” dealmaking environment and notes Lazard’s stock jumped 5% and was tied to a Warburg Pincus mandate involving Oxylabs. Lazard is $43.37, down 12.8% YTD.
5 min read
